Drug intelligence / Profile preview

GSK2820151

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK2820151 is an orally bioavailable small molecule inhibitor of the bromodomain and extra-terminal (BET) family of proteins, developed by GSK. It acts by inhibiting BET proteins, which are epigenetic readers involved in regulating gene expression through recognition of acetylated lysine residues on histone tails. By blocking these proteins, particularly BRD2, BRD3, and BRD4, GSK2820151 disrupts transcriptional programs that drive tumor growth and survival. The drug was investigated for its antineoplastic activity in advanced or recurrent solid tumors but development has been discontinued[1][2][3][4].

Other names: BET inhibitor GSK2820151

Targets

BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)

Beyond the preview

Go deeper on GSK2820151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2820151.

Explore the full profile